{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002831","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.545477+00:00","generated_at":"2026-06-18T12:00:22.678314+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Passage Bio reports FY2022 net loss of $136.1M; cash runway into H1 2025; clinical updates for GM1 and FTD","bullets":["Cash and marketable securities $189.6M at Dec 31, 2022, down from $315.8M; runway into first half of 2025.","FY2022 net loss $136.1M ($2.50 per share) vs $185.4M ($3.48) in 2021; R&D expenses $86.1M.","PBGM01 for GM1 gangliosidosis: interim data shows biological effect; plan to dose first patient at higher dose in H2 2023.","upliFT-D trial for FTD-GRN: enrollment ongoing; initial safety/biomarker data from Cohort 1 expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002831","json":"https://secwatch.observer/filing/0001558370-23-002831.json","markdown":"https://secwatch.observer/filing/0001558370-23-002831.md","text":"https://secwatch.observer/filing/0001558370-23-002831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/pasg-20230306x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:00:22.678314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b9fc8e28d93a1b300a8983dc73e834891118a39","claim":"Passage BIO, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss was $27.1 million, EPS $0.50 per basic and diluted share.","evidence_excerpt":"Net loss was $27.1 million, or a net loss of $0.50 per basic and diluted share, for the quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss was $27.1 million"},{"label":"EPS","value":"$0.50 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a1a677f02b7131791bc831e0d99c897ce8938688","claim":"Passage BIO, Inc. reported the year ended December 31, 2022 results: net income Net loss was $136.1 million, EPS $2.50 per basic and diluted share.","evidence_excerpt":"$136.1 million, or a net loss of $2.50 per basic and diluted share, for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $136.1 million"},{"label":"EPS","value":"$2.50 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}